RU2012114718A - Пиридиновые соединения конденсированного кольца как подтип-селективные модуляторы рецепторов сфингозин-1-фосфата-2 (s1p2) - Google Patents
Пиридиновые соединения конденсированного кольца как подтип-селективные модуляторы рецепторов сфингозин-1-фосфата-2 (s1p2) Download PDFInfo
- Publication number
- RU2012114718A RU2012114718A RU2012114718/04A RU2012114718A RU2012114718A RU 2012114718 A RU2012114718 A RU 2012114718A RU 2012114718/04 A RU2012114718/04 A RU 2012114718/04A RU 2012114718 A RU2012114718 A RU 2012114718A RU 2012114718 A RU2012114718 A RU 2012114718A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- group
- methoxy
- isopropyl
- independently selected
- Prior art date
Links
- 150000003222 pyridines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 claims abstract 48
- -1 methoxy, hydroxyl Chemical group 0.000 claims abstract 31
- 150000002825 nitriles Chemical class 0.000 claims abstract 20
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract 20
- 229910052736 halogen Inorganic materials 0.000 claims abstract 17
- 150000002367 halogens Chemical class 0.000 claims abstract 17
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 12
- 125000004122 cyclic group Chemical group 0.000 claims abstract 10
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract 10
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 9
- 125000003107 substituted aryl group Chemical group 0.000 claims abstract 7
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 7
- 229910052794 bromium Inorganic materials 0.000 claims abstract 5
- 229910052731 fluorine Inorganic materials 0.000 claims abstract 5
- 229910052740 iodine Inorganic materials 0.000 claims abstract 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims abstract 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- 102000011011 Sphingosine 1-phosphate receptors Human genes 0.000 claims abstract 2
- 108050001083 Sphingosine 1-phosphate receptors Proteins 0.000 claims abstract 2
- 239000005557 antagonist Substances 0.000 claims abstract 2
- 230000004071 biological effect Effects 0.000 claims abstract 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract 2
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 206010016654 Fibrosis Diseases 0.000 claims 4
- 206010020751 Hypersensitivity Diseases 0.000 claims 4
- 206010052428 Wound Diseases 0.000 claims 4
- 208000027418 Wounds and injury Diseases 0.000 claims 4
- 230000007815 allergy Effects 0.000 claims 4
- 208000030533 eye disease Diseases 0.000 claims 4
- 230000004761 fibrosis Effects 0.000 claims 4
- 208000019622 heart disease Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 230000006453 vascular barrier function Effects 0.000 claims 4
- 230000006806 disease prevention Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- CLBKKPYJCVVTTE-UHFFFAOYSA-N 1-(2,6-dichlorophenyl)-3-[(1,3-dimethyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea Chemical compound N=1C=2C(C)=NN(C)C=2C(C(C)C)=CC=1CNC(=O)NC1=C(Cl)C=CC=C1Cl CLBKKPYJCVVTTE-UHFFFAOYSA-N 0.000 claims 1
- LMABTFWHIPWRPC-UHFFFAOYSA-N 1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea Chemical compound N=1C=2C(C)=NN(C)C=2C(C(C)C)=CC=1CNC(=O)NC1=CC(Cl)=NC(Cl)=C1 LMABTFWHIPWRPC-UHFFFAOYSA-N 0.000 claims 1
- FPNRZKJVJGUCOW-UHFFFAOYSA-N 1-(2,6-dichloropyridin-4-yl)-3-[(4,8-dimethylquinolin-2-yl)amino]urea Chemical compound N1=C2C(C)=CC=CC2=C(C)C=C1NNC(=O)NC1=CC(Cl)=NC(Cl)=C1 FPNRZKJVJGUCOW-UHFFFAOYSA-N 0.000 claims 1
- XDQJLXNLJHENBK-UHFFFAOYSA-N 1-(2,6-dichloropyridin-4-yl)-3-[(4-methylquinolin-2-yl)amino]urea Chemical compound N=1C2=CC=CC=C2C(C)=CC=1NNC(=O)NC1=CC(Cl)=NC(Cl)=C1 XDQJLXNLJHENBK-UHFFFAOYSA-N 0.000 claims 1
- MSTNXXMGZNODPF-UHFFFAOYSA-N 1-(2-butoxy-6-chloropyridin-4-yl)-3-[(1,3-dimethyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea Chemical compound ClC1=NC(OCCCC)=CC(NC(=O)NCC=2N=C3C(C)=NN(C)C3=C(C(C)C)C=2)=C1 MSTNXXMGZNODPF-UHFFFAOYSA-N 0.000 claims 1
- VBJHQEDFVPOUBY-UHFFFAOYSA-N 1-(2-chloro-6-methoxypyridin-4-yl)-3-[(1,3-dimethyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea Chemical compound ClC1=NC(OC)=CC(NC(=O)NCC=2N=C3C(C)=NN(C)C3=C(C(C)C)C=2)=C1 VBJHQEDFVPOUBY-UHFFFAOYSA-N 0.000 claims 1
- UJYZFHIZYGZTEM-UHFFFAOYSA-N 1-(2-chloro-6-propoxypyridin-4-yl)-3-[(1,3-dimethyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea Chemical compound ClC1=NC(OCCC)=CC(NC(=O)NCC=2N=C3C(C)=NN(C)C3=C(C(C)C)C=2)=C1 UJYZFHIZYGZTEM-UHFFFAOYSA-N 0.000 claims 1
- IMIMBIWNJBKPKL-UHFFFAOYSA-N 1-(2-chloro-6-propylpyridin-4-yl)-3-[(1,3-dimethyl-7-propan-2-ylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea Chemical compound ClC1=NC(CCC)=CC(NC(=O)NCC=2N=C3C(C)=NN(C)C3=C(C(C)C)C=2)=C1 IMIMBIWNJBKPKL-UHFFFAOYSA-N 0.000 claims 1
- PTRPWZRYRPWCAX-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[(1,3,7-trimethylpyrazolo[4,3-b]pyridin-5-yl)methyl]urea Chemical compound N1=C2C(C)=NN(C)C2=C(C)C=C1CNC(=O)NC1=CC(Cl)=CC(Cl)=C1 PTRPWZRYRPWCAX-UHFFFAOYSA-N 0.000 claims 1
- XELXFTLTXOLAHQ-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[(4,5,8-trimethylquinolin-2-yl)amino]urea Chemical compound N1=C2C(C)=CC=C(C)C2=C(C)C=C1NNC(=O)NC1=CC(Cl)=CC(Cl)=C1 XELXFTLTXOLAHQ-UHFFFAOYSA-N 0.000 claims 1
- BKWSFLNRRIKSGC-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[(4,8-dimethylquinolin-2-yl)amino]urea Chemical compound N1=C2C(C)=CC=CC2=C(C)C=C1NNC(=O)NC1=CC(Cl)=CC(Cl)=C1 BKWSFLNRRIKSGC-UHFFFAOYSA-N 0.000 claims 1
- IZYXAFZDAPSOAV-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[(4-methyl-1,8-naphthyridin-2-yl)amino]urea Chemical compound N=1C2=NC=CC=C2C(C)=CC=1NNC(=O)NC1=CC(Cl)=CC(Cl)=C1 IZYXAFZDAPSOAV-UHFFFAOYSA-N 0.000 claims 1
- OWXCWZQVBWXWBH-UHFFFAOYSA-N 1-(3,5-dichlorophenyl)-3-[(4-propan-2-ylquinolin-2-yl)amino]urea Chemical compound N=1C2=CC=CC=C2C(C(C)C)=CC=1NNC(=O)NC1=CC(Cl)=CC(Cl)=C1 OWXCWZQVBWXWBH-UHFFFAOYSA-N 0.000 claims 1
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 1
- RJSYPKWVIJGNLO-UHFFFAOYSA-N CCOClOC Chemical compound CCOClOC RJSYPKWVIJGNLO-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- DUIOPKIIICUYRZ-UHFFFAOYSA-N semicarbazide Chemical compound NNC(N)=O DUIOPKIIICUYRZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24664209P | 2009-09-29 | 2009-09-29 | |
| US61/246,642 | 2009-09-29 | ||
| PCT/US2010/050486 WO2011041287A1 (en) | 2009-09-29 | 2010-09-28 | Condensed ring pyridine compounds as subtype-selective modulators of sphingosine-1-phosphate-2 (s1p2) receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012114718A true RU2012114718A (ru) | 2013-11-10 |
Family
ID=43031503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012114718/04A RU2012114718A (ru) | 2009-09-29 | 2010-09-28 | Пиридиновые соединения конденсированного кольца как подтип-селективные модуляторы рецепторов сфингозин-1-фосфата-2 (s1p2) |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US8507682B2 (enExample) |
| EP (1) | EP2483245A1 (enExample) |
| JP (1) | JP2013506003A (enExample) |
| KR (1) | KR20120087932A (enExample) |
| CN (1) | CN102741232A (enExample) |
| AU (1) | AU2010300791A1 (enExample) |
| BR (1) | BR112012007095A2 (enExample) |
| CA (1) | CA2775587A1 (enExample) |
| IL (1) | IL218843A0 (enExample) |
| MX (1) | MX2012003718A (enExample) |
| NZ (1) | NZ599595A (enExample) |
| RU (1) | RU2012114718A (enExample) |
| SG (1) | SG10201406178WA (enExample) |
| WO (1) | WO2011041287A1 (enExample) |
| ZA (1) | ZA201202366B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013240139B2 (en) | 2012-03-26 | 2017-02-23 | Arroyo Biosciences L.L.C. | Novel sphingosine 1-phosphate receptor antagonists |
| WO2014158302A1 (en) * | 2013-03-25 | 2014-10-02 | Swenson Rolf Eric | Novel sphingosine 1-phosphate receptor antagonists |
| EP3148550B1 (en) * | 2014-06-02 | 2020-10-28 | Dalhousie University | Treatment of familial exudative vitreoretinopathy through s1pr2 inhibition |
| US10487082B2 (en) | 2015-06-01 | 2019-11-26 | Dalhousie University | S1PR2 antagonists and uses therefor |
| US10858358B2 (en) | 2015-06-01 | 2020-12-08 | Dalhousie University | S1PR2 antagonists and uses therefor |
| AU2016273436B2 (en) * | 2015-06-01 | 2021-01-28 | Dalhousie University | S1PR2 antagonists and uses therefor |
| CN107382965A (zh) * | 2017-08-14 | 2017-11-24 | 河南科技大学第附属医院 | 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法 |
| CN113896646B (zh) * | 2020-07-06 | 2023-06-02 | 浙江海森药业股份有限公司 | 一种4-甲基-3-氧代-n-苯基戊酰胺的高效绿色制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0146810A3 (de) | 1983-12-05 | 1987-05-13 | Solco Basel AG | Verfahren zur Herstellung von Sphingosinderivaten |
| US5110987A (en) | 1988-06-17 | 1992-05-05 | Emory University | Method of preparing sphingosine derivatives |
| NZ233285A (en) | 1989-04-18 | 1992-06-25 | Duphar Int Res | Imidazole-substituted carbamoyl-indoles and condensed analogues thereof and pharmaceutical compositions |
| US5294722A (en) | 1992-04-16 | 1994-03-15 | E. R. Squibb & Sons, Inc. | Process for the preparation of imidazoles useful in angiotensin II antagonism |
| US5403851A (en) | 1994-04-05 | 1995-04-04 | Interneuron Pharmaceuticals, Inc. | Substituted tryptamines, phenalkylamines and related compounds |
| ATE314342T1 (de) | 1997-03-12 | 2006-01-15 | Takara Bio Inc | Spingosinanaloga |
| WO1999012890A1 (fr) | 1997-09-11 | 1999-03-18 | Takara Shuzo Co., Ltd. | Derives de sphingosine et composition medicamenteuse |
| WO2001098301A1 (en) * | 2000-06-20 | 2001-12-27 | Japan Tobacco Inc. | Pyrazolopyridine compounds and use thereof as drugs |
| US20020183762A1 (en) | 2001-06-01 | 2002-12-05 | Ams Research Corporation | Bone anchor inserters and methods |
| US7074817B2 (en) | 2001-06-20 | 2006-07-11 | Wyeth | Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) |
| JPWO2003020313A1 (ja) * | 2001-09-04 | 2004-12-16 | 小野薬品工業株式会社 | スフィンゴシン−１−リン酸受容体調節剤からなる呼吸器疾患治療剤 |
| AU2002354476A1 (en) * | 2001-12-14 | 2003-06-30 | Japan Tobacco Inc. | Pyrazolopyridine derivatives and medicinal use thereof |
| GB0206876D0 (en) * | 2002-03-22 | 2002-05-01 | Merck Sharp & Dohme | Therapeutic agents |
| CN1656079A (zh) | 2002-05-31 | 2005-08-17 | 卫材株式会社 | 吡唑化合物和含有该化合物的药物组合物 |
| US20090004207A1 (en) | 2007-06-08 | 2009-01-01 | Timothy Tun Hla | Methods and Compositions for Inhibiting Pathological Angiogenesis in the Eye |
| WO2009074969A2 (en) * | 2007-12-12 | 2009-06-18 | University Of Lausanne | Sphingosine-1-phosphate, analogs and antagonists for use as medicaments |
-
2010
- 2010-09-28 CA CA2775587A patent/CA2775587A1/en not_active Abandoned
- 2010-09-28 JP JP2012532230A patent/JP2013506003A/ja active Pending
- 2010-09-28 RU RU2012114718/04A patent/RU2012114718A/ru not_active Application Discontinuation
- 2010-09-28 NZ NZ599595A patent/NZ599595A/en not_active IP Right Cessation
- 2010-09-28 WO PCT/US2010/050486 patent/WO2011041287A1/en not_active Ceased
- 2010-09-28 US US13/498,499 patent/US8507682B2/en not_active Expired - Fee Related
- 2010-09-28 CN CN2010800492699A patent/CN102741232A/zh active Pending
- 2010-09-28 KR KR1020127010718A patent/KR20120087932A/ko not_active Withdrawn
- 2010-09-28 MX MX2012003718A patent/MX2012003718A/es active IP Right Grant
- 2010-09-28 BR BR112012007095A patent/BR112012007095A2/pt not_active IP Right Cessation
- 2010-09-28 SG SG10201406178WA patent/SG10201406178WA/en unknown
- 2010-09-28 EP EP10763267A patent/EP2483245A1/en not_active Withdrawn
- 2010-09-28 AU AU2010300791A patent/AU2010300791A1/en not_active Abandoned
-
2012
- 2012-03-26 IL IL218843A patent/IL218843A0/en unknown
- 2012-04-02 ZA ZA2012/02366A patent/ZA201202366B/en unknown
-
2013
- 2013-06-27 US US13/929,451 patent/US8703797B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US8507682B2 (en) | 2013-08-13 |
| NZ599595A (en) | 2014-03-28 |
| US8703797B2 (en) | 2014-04-22 |
| BR112012007095A2 (pt) | 2016-04-19 |
| AU2010300791A1 (en) | 2012-04-19 |
| CN102741232A (zh) | 2012-10-17 |
| MX2012003718A (es) | 2012-06-28 |
| US20130296361A1 (en) | 2013-11-07 |
| SG10201406178WA (en) | 2014-11-27 |
| US20120208840A1 (en) | 2012-08-16 |
| WO2011041287A1 (en) | 2011-04-07 |
| CA2775587A1 (en) | 2011-04-07 |
| ZA201202366B (en) | 2012-12-27 |
| JP2013506003A (ja) | 2013-02-21 |
| KR20120087932A (ko) | 2012-08-07 |
| IL218843A0 (en) | 2012-06-28 |
| EP2483245A1 (en) | 2012-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2324687C2 (ru) | Производные бензотиазола, характеризующиеся агонистической активностью к бета-2-адренорецепторам | |
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| JP2007505877A5 (enExample) | ||
| JP2012521428A5 (enExample) | ||
| RU2009103675A (ru) | Производные бензимидазола в лечении расстройств, ассоциированных с ванилоидным рецептором trpv1 | |
| RU2003135482A (ru) | Геропротектор на основе гидрированных пиридо(4,3-b) индолов (варианты), фармакологическое средство на его основе и способ его применения | |
| PE20141674A1 (es) | Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar | |
| JP2013506003A5 (enExample) | ||
| JP2004518723A5 (enExample) | ||
| JP2013533253A5 (enExample) | ||
| RU2017138549A (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| EA201000024A1 (ru) | Новые производные дикарбоновых кислот в качестве агонистов рецептора s1p1 | |
| JP2013531008A5 (enExample) | ||
| JP2016503797A5 (enExample) | ||
| RU2013155586A (ru) | [1,3]оксазины | |
| RU2009123525A (ru) | ПРОИЗВОДНЫЕ 5-СУЛЬФАНИЛМЕТИЛ[1,2,4}ТРИАЗОЛ[1,5-а]ПИРИМИДИН-7-ОЛА В КАЧЕСТВЕ АНТАГОНИСТОВ CXCR2 | |
| RU2012114602A (ru) | Замещенные дигидробензоциклоалкилоксиметил оксазолопиримидиноны, их получение и применение | |
| RU2009136592A (ru) | Терапевтические агенты | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| JP2006501201A5 (enExample) | ||
| RU2008119692A (ru) | Новые 1-азабициклоалкилпроизводные для лечения психических растройств | |
| RU2435760C2 (ru) | 1н-хиназолин-2,4-дионы | |
| RU2394031C2 (ru) | Соли четвертичного аммония в качестве антагонистов м3 | |
| RU2389719C3 (ru) | Ненуклеозидные ингибиторы обратной транскриптазы | |
| RU2007130144A (ru) | Гетероциклические соединения в качестве антагонистов cccr2b |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20141010 |